Insmed (INSM) Stock Forecast & Price Target

$75.68 +1.59 (+2.15%)

(As of 11/26/2024 ET)

Insmed - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 16 Analyst Ratings

Sell
0

Hold
0

Buy
16

Based on 16 Wall Street analysts who have issued ratings for Insmed in the last 12 months, the stock has a consensus rating of "Buy." Out of the 16 analysts, 16 have given a buy rating for INSM.

Consensus Price Target

$83.67
10.55% Upside

According to the 16 analysts' twelve-month price targets for Insmed, the average price target is $83.67. The highest price target for INSM is $105.00, while the lowest price target for INSM is $42.00. The average price target represents a forecasted upside of 10.55% from the current price of $75.68.

Get the Latest News and Ratings for INSM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Insmed and its competitors.

INSM Analyst Ratings Over Time

Type	Current Forecast 11/27/23 to 11/26/24	1 Month Ago 10/28/23 to 10/27/24	3 Months Ago 8/29/23 to 8/28/24	1 Year Ago 11/27/22 to 11/27/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	16 Buy rating(s)	16 Buy rating(s)	11 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$83.67	$82.73	$79.19	$41.27
Forecasted Upside	10.55% Upside	16.59% Upside	3.47% Upside	72.40% Upside
Consensus Rating	Buy	Buy	Buy	Buy

New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!

INSM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

INSM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Insmed Stock vs. The Competition

Type	Insmed	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	11.63% Upside	24,931.24% Upside	6.94% Upside
News Sentiment Rating	Positive News See Recent INSM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
11/22/2024	JPMorgan Chase & Co. 3 of 5 stars	Boost Target	Overweight ➝ Overweight	$74.00 ➝ $83.00	+12.73%
11/1/2024	Truist Financial 2 of 5 stars	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $105.00	+55.79%
11/1/2024	HC Wainwright 2 of 5 stars	Reiterated Rating	Buy ➝ Buy	$90.00 ➝ $90.00	+33.77%
10/9/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$84.00 ➝ $86.00	+23.05%
9/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
8/9/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$75.00 ➝ $98.00	+32.90%
JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad) Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late.
8/9/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$78.00 ➝ $84.00	+15.67%
8/9/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$74.00 ➝ $88.00	+22.55%
7/12/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$60.00 ➝ $85.00	+11.07%
7/10/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$74.00 ➝ $102.00	+42.98%
7/9/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$70.00 ➝ $95.00	+36.08%
6/21/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$42.00 ➝ $75.00	+12.83%
6/7/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$36.00 ➝ $82.00	+43.43%
5/29/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$55.00 ➝ $77.00	+58.66%
5/29/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$40.00 ➝ $63.00	+31.09%
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$42.00	+53.06%
2/24/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$46.00	+128.40%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:39 PM ET.

INSM Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Insmed is $83.67, with a high forecast of $105.00 and a low forecast of $42.00.
: 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last twelve months. There are currently 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INSM shares.
: According to analysts, Insmed's stock has a predicted upside of 10.55% based on their 12-month stock forecasts.
: Insmed has been rated by research analysts at Bank of America, Cantor Fitzgerald, HC Wainwright, JPMorgan Chase & Co., and Truist Financial in the past 90 days.
: Analysts like Insmed more than other "medical" companies. The consensus rating for Insmed is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how INSM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

This page (NASDAQ:INSM) was last updated on 11/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insmed (INSM) Stock Forecast & Price Target